To Evaluate the Safety and Clinial Radiological Outcomes in 2 Years of Embrance Model Reverse Shoulder Arthroplasty

Sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal (Other)
Overall Status
Recruiting
CT.gov ID
NCT05569161
Collaborator
(none)
250
1
48
5.2

Study Details

Study Description

Brief Summary

The use of inverted prostheses to replace shoulder joints damaged by degenerative or traumatic processes has become widespread over the past three decades. Current designs, used correctly, can restore function and improve pain in the majority of patients in whom they are implanted.

However, there are complications associated with shoulder arthroplasty surgery, such as wear of the prosthetic components, infection, allergy to the prosthetic components, or failure to restore full shoulder function. The occurrence of these complications is affected by multiple factors dependent on the subject, the surgeon and/or the implant used.

The EMBRACE Reverse Shoulder Arthroplasty System (LINK Spain) is a new model of reverse shoulder prosthesis introduced to the European market in August 2020. It is authorised for use in the treatment of degenerative or traumatic processes of the shoulder in the European Community. It has been in regular use at our centre since October 2020, and more than 50 prostheses of this model have been implanted this year.

There is an ongoing study at the Hospital Universitario Ramón y Cajal, with code PROTESISHOMBRO01, which carries out a prospective registry of all shoulder prostheses implanted at the centre. The present study, PROTESISHOMBRO02, will be carried out in conjunction with this one and differs from the previous one in that: 1.-It carries out a somewhat more exhaustive analysis of a subgroup of the patients included in the PROTESISHOMBRO01 study, and 2. The aim is to carry out a more detailed follow-up of the subjects who are implanted with this prosthetic model on a primary basis, analysing the clinical and radiological results and evaluating the presence of adverse effects of the prosthesis or short-term complications. For this purpose, subjects will be closely monitored for two years.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    250 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Prospective Multicentr Longitudinal Study to Evaluate the Safet and Clinical Radiological Outcomes in the First Two Years of the Ambrace Model Reverse Shoulder Arthroplasty.
    Actual Study Start Date :
    Mar 24, 2022
    Anticipated Primary Completion Date :
    Mar 24, 2024
    Anticipated Study Completion Date :
    Mar 24, 2026

    Outcome Measures

    Primary Outcome Measures

    1. To assess the safety and the clinical and radiological outcome of Embrace primary reverse shoulder prostheses. [24 months]

      survival at 2-year follow-up with computerized tomografhic

    Secondary Outcome Measures

    1. security [24 months]

      presence of possible adverse effects or complications, implant-related or not, including infection, mechanical complications of the implant, dislocation, fracture, loosening, readmission, reoperation or fracture.

    2. efficiency [24 months]

      To evaluate the effect of the Embrace Reverse Embrace arthroplasty on postoperative pain and functional outcome. This is evaluate with computerized tomographic.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients who, after receiving information about the study design, the aims of the study, the possible risks that may arise from it and the fact that they may refuse to participate at any time, give their written consent to participate in the study.

    • Be over 18 years of age.

    • Have a shoulder joint disorder that is amenable to treatment with an Embrace reverse arthroplasty.

    • Have a CT or MRI scan performed no more than 6 months prior to surgery.

    Translated with www.DeepL.com/Translator (free version)

    Exclusion Criteria:
    • Patients who have undergone arthroplasty of any type on the ipsilateral shoulder.

    • Patients with an active infection at any site at the time of shoulder surgery.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Miguel Ángel Ruiz Ibán Madrid Spain 28034

    Sponsors and Collaborators

    • Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
    ClinicalTrials.gov Identifier:
    NCT05569161
    Other Study ID Numbers:
    • PROTESISHOMBRO02
    First Posted:
    Oct 6, 2022
    Last Update Posted:
    Oct 6, 2022
    Last Verified:
    Oct 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Oct 6, 2022